TRVI MEXC RealStocks
Own real TRVI shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 06:48:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Trevi Therapeutics, Inc. (TRVI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $13.53, with a market capitalization of $1.93B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $9.82 to $20.22. This page covers its latest market performance, valuation, price trends and company information.
$1.93B | |
$13.39 | |
$13.95 | |
$13.29 | |
$13.51 | |
1.71M | |
1.98M | |
-- | |
$20.22 | |
$9.82 | |
-- | |
2026-09-30 |
Trevi Therapeutics, Inc. (TRVI) last closed at $13.53 as of 2026-11-19 00:31:00, up 0.07% ($0.01) from the previous close of $13.51.
During the latest regular trading session, TRVI traded between $13.29 and $13.95, with a volume of 1.71M shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Trevi Therapeutics, Inc. (TRVI) moved from $14.91 to $13.53, representing a decline of 9.24% ($1.38).
The stock traded between $12.89 and $15.25 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.77 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 35.7%
TRVI is currently trading at $13.53, placing it 35.7% of the way from its 52-week low of $9.82 to its 52-week high of $20.22. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 34 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Trevi Therapeutics, Inc. (TRVI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to TRVI, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between TRVI shares and USD.
TRVI Shares to USD
1.00 TRVI shares = 13.533 USD
Calculations are estimates based on the latest available price and are for reference only.